113 related articles for article (PubMed ID: 18499489)
1. The structure of human serotonin 2c G-protein-coupled receptor bound to agonists and antagonists.
Bray JK; Goddard WA
J Mol Graph Model; 2008 Aug; 27(1):66-81. PubMed ID: 18499489
[TBL] [Abstract][Full Text] [Related]
2. Insights into the influence of 5-HT2c aminoacidic variants with the inhibitory action of serotonin inverse agonists and antagonists.
Galeazzi R; Massaccesi L; Piva F; Principato G; Laudadio E
J Mol Model; 2014 Mar; 20(3):2120. PubMed ID: 24562856
[TBL] [Abstract][Full Text] [Related]
3. Pharmacophore-directed homology modeling and molecular dynamics simulation of G protein-coupled receptor: study of possible binding modes of 5-HT2C receptor agonists.
Zuo Z; Chen G; Luo X; Puah C; Zhu W; Chen K; Jiang H
Acta Biochim Biophys Sin (Shanghai); 2007 Jun; 39(6):413-22. PubMed ID: 17558446
[TBL] [Abstract][Full Text] [Related]
4. Predicted structures and dynamics for agonists and antagonists bound to serotonin 5-HT2B and 5-HT2C receptors.
Kim SK; Li Y; Abrol R; Heo J; Goddard WA
J Chem Inf Model; 2011 Feb; 51(2):420-33. PubMed ID: 21299232
[TBL] [Abstract][Full Text] [Related]
5. 5-HT
Peng Y; McCorvy JD; Harpsøe K; Lansu K; Yuan S; Popov P; Qu L; Pu M; Che T; Nikolajsen LF; Huang XP; Wu Y; Shen L; Bjørn-Yoshimoto WE; Ding K; Wacker D; Han GW; Cheng J; Katritch V; Jensen AA; Hanson MA; Zhao S; Gloriam DE; Roth BL; Stevens RC; Liu ZJ
Cell; 2018 Feb; 172(4):719-730.e14. PubMed ID: 29398112
[TBL] [Abstract][Full Text] [Related]
6. Identification of structural determinants of ligand selectivity in 5-HT₂ receptor subtypes on the basis of protein-ligand interactions.
Jang JW; Kim MS; Cho YS; Cho AE; Pae AN
J Mol Graph Model; 2012 Sep; 38():342-53. PubMed ID: 23085173
[TBL] [Abstract][Full Text] [Related]
7. Identification of the binding sites and selectivity of sarpogrelate, a novel 5-HT2 antagonist, to human 5-HT2A, 5-HT2B and 5-HT2C receptor subtypes by molecular modeling.
Rashid M; Manivet P; Nishio H; Pratuangdejkul J; Rajab M; Ishiguro M; Launay JM; Nagatomo T
Life Sci; 2003 May; 73(2):193-207. PubMed ID: 12738034
[TBL] [Abstract][Full Text] [Related]
8. Vasoconstrictor responses to 5-hydroxytryptamine in the autoperfused hindquarters of spontaneously hypertensive rats.
Calama E; Morán A; Ortiz de Urbina AV; Martín ML; San Román L
Pharmacology; 2004 Jun; 71(2):66-72. PubMed ID: 15118345
[TBL] [Abstract][Full Text] [Related]
9. Predictive in silico studies of human 5-hydroxytryptamine receptor subtype 2B (5-HT2B) and valvular heart disease.
Reid TE; Kumar K; Wang XS
Curr Top Med Chem; 2013; 13(11):1353-62. PubMed ID: 23675941
[TBL] [Abstract][Full Text] [Related]
10. Development of homogeneous high-affinity agonist binding assays for 5-HT2 receptor subtypes.
Song J; Hanniford D; Doucette C; Graham E; Poole MF; Ting A; Sherf B; Harrington J; Brunden K; Stricker-Krongrad A
Assay Drug Dev Technol; 2005 Dec; 3(6):649-59. PubMed ID: 16438660
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and SAR of 2,3,3a,4-tetrahydro-1H-pyrrolo[3,4-c]isoquinolin-5(9bH)-ones as 5-HT2C receptor agonists.
Fevig JM; Feng J; Rossi KA; Miller KJ; Wu G; Hung CP; Ung T; Malmstrom SE; Zhang G; Keim WJ; Cullen MJ; Rohrbach KW; Qu Q; Gan J; Pelleymounter MA; Robl JA
Bioorg Med Chem Lett; 2013 Jan; 23(1):330-5. PubMed ID: 23177783
[TBL] [Abstract][Full Text] [Related]
12. SAR of psilocybin analogs: discovery of a selective 5-HT 2C agonist.
Sard H; Kumaran G; Morency C; Roth BL; Toth BA; He P; Shuster L
Bioorg Med Chem Lett; 2005 Oct; 15(20):4555-9. PubMed ID: 16061378
[TBL] [Abstract][Full Text] [Related]
13. Lorcaserin, a novel selective human 5-hydroxytryptamine2C agonist: in vitro and in vivo pharmacological characterization.
Thomsen WJ; Grottick AJ; Menzaghi F; Reyes-Saldana H; Espitia S; Yuskin D; Whelan K; Martin M; Morgan M; Chen W; Al-Shamma H; Smith B; Chalmers D; Behan D
J Pharmacol Exp Ther; 2008 May; 325(2):577-87. PubMed ID: 18252809
[TBL] [Abstract][Full Text] [Related]
14. Computational design of thermostabilizing point mutations for G protein-coupled receptors.
Popov P; Peng Y; Shen L; Stevens RC; Cherezov V; Liu ZJ; Katritch V
Elife; 2018 Jun; 7():. PubMed ID: 29927385
[TBL] [Abstract][Full Text] [Related]
15. Selective 5-HT2C receptor agonists: Design and synthesis of pyridazine-fused azepines.
Green MP; McMurray G; Storer RI
Bioorg Med Chem Lett; 2016 Aug; 26(16):4117-21. PubMed ID: 27381086
[TBL] [Abstract][Full Text] [Related]
16. Novel structural insights for drug design of selective 5-HT(2C) inverse agonists from a ligand-biased receptor model.
Renault N; Gohier A; Chavatte P; Farce A
Eur J Med Chem; 2010 Nov; 45(11):5086-99. PubMed ID: 20880612
[TBL] [Abstract][Full Text] [Related]
17. Antiallodynic effects of intrathecally administered 5-HT(2C) receptor agonists in rats with nerve injury.
Obata H; Saito S; Sakurazawa S; Sasaki M; Usui T; Goto F
Pain; 2004 Mar; 108(1-2):163-9. PubMed ID: 15109520
[TBL] [Abstract][Full Text] [Related]
18. Serotonin 5-HT(2C) receptor homodimerization is not regulated by agonist or inverse agonist treatment.
Herrick-Davis K; Grinde E; Weaver BA
Eur J Pharmacol; 2007 Jul; 568(1-3):45-53. PubMed ID: 17507008
[TBL] [Abstract][Full Text] [Related]
19. Molecular determinants for the interaction of the valvulopathic anorexigen norfenfluramine with the 5-HT2B receptor.
Setola V; Dukat M; Glennon RA; Roth BL
Mol Pharmacol; 2005 Jul; 68(1):20-33. PubMed ID: 15831837
[TBL] [Abstract][Full Text] [Related]
20. Effect of 5-hydroxytryptamine on neurogenic vasoconstriction in the isolated, autoperfused hindquarters of the rat.
Calama E; Ortíz de Urbina AV; Morán A; Martín ML; San Román L
Clin Exp Pharmacol Physiol; 2005 Oct; 32(10):894-900. PubMed ID: 16173953
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
